BioMedWire Stocks

Loss of Y Chromosomes in Older Men Elevates Heart Disease Risk, Study Finds

A new study has found that older men losing the Y chromosome in their white blood cells as they age can heighten their risk of death from cardiovascular illnesses and cause severe heart problems. This genetic change, which is scientifically referred to as mosaic Loss of y or mLOY, impacts about 20% of men aged 60 and 40% of those aged 70 and above.

The study was carried out by researchers at Sweden’s Uppsala University and the University of Virginia. It was led by Professor Kenneth Walsh of the School of Medicine at the University of Virginia and Associate Professor Lars Forsberg of Uppsala’s Department of Immunology, Genetics and Pathology.

Forsberg explained that this chromosome was lost during cell division and was common in organs and tissues with high rates of cell division, noting that replicated risk factors included smoking, age and genetic predisposition.

The objective of the study was to establish a causal link between the loss of the Y chromosome and impaired heart function, the development of fibrosis in the heart and death of men as a result of cardiovascular illnesses. Nonischemic heart failure, which is a form of heart failure that isn’t caused by blockages in arteries in the heart, is one of the heart diseases associated with mLOY.

For their study, the investigators used the CRISPR gene editing tool to extract the Y chromosome from white blood cells in mice. They found that this loss caused direct damage to the internal organs of these animals, noting that the animals with mLOY died younger in comparison to those who still had the chromosome.

In their report, the researchers explained that the loss of the Y chromosome in cardiac macrophages stimulated the TGF-β1 pathway, which in turn increased scarring of the heart. Cardiac macrophages are white blood cells found in the heart muscle. When the scientists blocked this signaling pathway, they discovered that the pathological changes caused by the Y chromosome’s loss could be reversed.

In their report, Forsberg explained that routinely testing for mLOY in blood cells may help prevent cardiovascular illnesses in aging males. He also added that routine testing for the loss of the Y chromosome in blood cells could help prevent cardiovascular disease.

Prior studies have found that the loss of the Y chromosome may also be linked to excessive fibrosis in the lungs and the kidneys. Researchers are currently focused on developing a genetic screening test that can evaluate mLOY risk. As those genetic tests are being developed, older people would be well advised to make use of the available technologies, such as those availed by Odyssey Health Inc. (OTC: ODYY), to monitor for cardiac complications so that treatment can be commenced without delay.

NOTE TO INVESTORS: The latest news and updates relating to Odyssey Health Inc. (OTC: ODYY) are available in the company’s newsroom at https://ibn.fm/ODYY

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape

The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…

2 days ago

New Compound Could Become a Transformational Brain Cancer Pill

Researchers at the University of Chicago have identified a compound that has shown efficacy in shrinking tumors in…

2 days ago

Circadian Regulation Could Boost Cancer Immunotherapy, New Study Finds

Scientists have found that keeping circadian rhythms, the variations in body processes during the course…

3 days ago

The 47% Signal: Why Earth Science Tech Inc.’s (ETST) Management Is Betting the House on ETST

While many capitalization structures are diluted in the landscape of over-the-counter (“OTC”) markets, Earth Science…

3 days ago

The US Formally Exits the World Health Organization

The United States has formally communicated its immediate withdrawal from the World Health Organization (WHO), denying…

5 days ago

Meta Analysis Finds That Weight Reduction Reduces Severity of Psoriasis

Psoriasis is a chronic skin condition that afflicts at least 60 million individuals globally. Nearly 80% of these affected people also…

1 week ago